Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04856982 · ClinicalTrials.gov registry record · Phase 3
A Study of BIIB067 (Tofersen) Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation
A Phase 3 study of Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation, sponsored by Biogen.
- Active
- Registry status
- Phase 3
- Development phase
- 158
- Enrollment target
- 20
- Study locations
NCT04856982: Active Phase 3 study of Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation, sponsored by Biogen.
NCT04856982 is a Phase 3 study of Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation that is active but no longer recruiting, run by Biogen. The registered enrollment target is 158 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (80% lower). The trial reports 20 study locations across 18 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04856982, a Phase 3 study of Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation, is active but no longer recruiting, sponsored by Biogen.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 158 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study is to evaluate the efficacy of tofersen in presymptomatic adult carriers of a superoxide dismutase 1 (SOD1) mutation with elevated neurofilament (NF). The secondary objectives of this study are to evaluate the safety and tolerability tofersen and to evaluate the effect of tofersen on pharmacodynamics (PD)/treatment response biomarkers when initiated prior to versus at the time of emergence of clinically manifest amyotrophic lateral sclerosis (ALS).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Tofersen
Study Locations (20)
California
- University of California San Diego Medical Center - La Jolla
- California Pacific Medical Center Research Institute - San Francisco
Florida
- Holy Cross Hospital Phil Smith Neuroscience Institute - Fort Lauderdale
- University of Miami School of Medicine - Miami
Arizona
- HonorHealth Neurology - Scottsdale
Georgia
- The Emory Clinic - Atlanta
Illinois
- Northwestern Medicine - Chicago
Maryland
- Johns Hopkins Hospital - Baltimore
Massachusetts
- Massachusetts General Hospital - Charlestown
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 158 participants |
| Start Date | 2021-05-17 |
| Est. Completion | 2027-08-07 |
| Phase | Phase 3 |
What the registry record for NCT04856982 still lists
NCT04856982 is an interventional study that assigns participants to a tested intervention. The registered 158 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (80% lower).
The record links to 1 condition, with Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04856982 names 20 study sites across 18 states, led by California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT04856982 about?
NCT04856982 is a clinical study titled "A Study of BIIB067 (Tofersen) Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation". The primary objective of this study is to evaluate the efficacy of tofersen in presymptomatic adult carriers of a superoxide dismutase 1 (SOD1) mutation with elevated neurofilament (NF). The secondary objectives of this study are to evaluate the safety and tolerability tofersen and to evaluate the e...
What is the current status of trial NCT04856982?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 158 participants. The study started on 2021-05-17. Estimated completion is 2027-08-07.
What conditions does trial NCT04856982 study?
This clinical trial studies the following conditions: Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation.
What interventions are being tested in trial NCT04856982?
The interventions under investigation include: Placebo (DRUG), Tofersen (DRUG).
Who is sponsoring clinical trial NCT04856982?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04856982 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04856982's enrollment target sits among peer trials
158 1502nd of 2000 higher than 496 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04486833 · 158 participants · Phase 1
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
- NCT04697966 · 158 participants · NA
Mechanisms and Predictors of Change in App-Based Mindfulness Training for Adolescents
- NCT04969835 · 158 participants · Phase 1
A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
- NCT05230732 · 158 participants · NA
Neuromodulation of Inflammation and Endothelial Function
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI